Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer

Clinical Cancer Research

Volumn 10, Issue 16, 2004, Pages 5375-5380

  Núñez, Nomelí P ^a   Jelovac, Danijela ^b   Macedo, Luciana ^b   Berrigan, David ^a   Perkins, Susan N ^a   Hursting, Stephen D ^a   Barrett, J Carl ^a   Brodie, Angela ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; GONADOTROPIN; HORMONE; LETROZOLE; SOMATOMEDIN C; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RISK; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEEDBACK SYSTEM; FEMALE; GENETIC TRANSFECTION; GROWTH INHIBITION; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERPLASIA; MODEL; MOUSE; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; UTERUS WEIGHT;

ANIMALS; ANTINEOPLASTIC AGENTS; AROMATASE; BODY COMPOSITION; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, NUDE; MICE, TRANSGENIC; NITRILES; OVARIECTOMY; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS; TRIAZOLES;

EID: 4143140907     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0261     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts and Figures 2003. Atlanta, GA: American Cancer Society; 2003.
2. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst (Bethesda) 2003;95:1276-99.
3. Vogel VG. Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol 2001;19:87S-92S.
4. Brown K. Breast cancer chemoprevention: risk-benefit effects of the antiestrogen tamoxifen. Expert Opin Drug Saf 2002;1:253-67.
5. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole (Femara) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606.
6. Brodie A. Aromatase inhibitors and the application to the treatment of breast cancer. In: Pasqualini J, editor. Breast cancer: prognosis, treatment and prevention. New York: Marcel Dekker; 2002. p. 251-70.
7. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
8. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
9. Long BJ, Jelovac D, Handratta V, et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst (Bethesda) 2004;96:456-65.
10. Ruenitz PC, Shen Y, Li M, et al. Specific bone-protective effects of metabolites/derivatives of tamoxifen and clomiphene in ovariectomized rats. Bone 1998;23:537-42.
11. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Investig 2002;110:771-81.
12. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002;3:298-302.
13. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology (Basel) 2002;63:317-32.
14. Wu Y, Yakar S, Zhao L, Hennighausen L, Le Roith D. Circulating insulin-like growth factor-1 levels regulate colon cancer growth and metastasis. Cancer Res 2002;62:1030-5.
15. Wang Q, Bing C, Al-Barazanji K, et al. Interactions between leptin and hypothalamic neuropeptide Y neurons in the control of food intake and energy homeostasis in the rat. Diabetes 1997;46:335-41.
16. Hu X, Juneja SC, Maihle NJ, Cleary MP. Leptin: a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst (Bethesda) 2002;94:1704-11.
17. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305-17.
18. Lien EA, Johannessen DC, Aakvaag A, Lonning PE. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. J Steroid Biochem Mol Biol 1992;41:541-3.
19. Eng-Wong J, Hursting SD, Venzon D, Perkins SN, Zujewski JA. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomark Prev 2003;12:1468-73.
20. Yue W, Wang J, Savinov A, Brodie A. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res 1995;55:3073-7.
21. Lu Q, Liu Y, Long BJ, et al. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 1999;57:183-92.
22. Nagy TR, Clair AL. Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res 2000;8:392-8.
23. Mai V, Colbert LH, Berrigan D, et al. Calorie restriction and diet composition modulate spontaneous intestinal tumorigenesis in Apc (Min) mice through different mechanisms. Cancer Res 2003;63:1752-5.
24. Lee PD, Baker BK, Liu F, Kwan EY, Hintz RL. A homologous radioimmunoassay for rat insulin-like growth factor-I (IGF-1): implications for studies of human IGF-1 physiology. J Clin Endocrinol Metab 1996;81:2002-5.
25. Packard GC, Boardman TJ. The misuse of ratios, indexes, and percentages in ecophysiological research. Physiol Zool 1988;61:1-9.
26. Jordan VC. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 1995;35:195-211.
27. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (Bethesda) 1998;90:1371-88.
28. Kalu DN, Salerno E, Liu CC, et al. A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner 1991;15:109-23.
29. Stygar D, Muravitskaya N, Eriksson B, Eriksson H, Sahlin L. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol 2003;1:40-7.
30. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003;8:335-41.
31. Ke HZ, Chen HK, Simmons HA, et al. Comparative effects of roloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 1997;20:31-9.
32. Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Investig 2000;106:1229-37.